Evidence map›Paper›PMID 30132246›Full record

ArticleChinese journal of integrative medicine2019

Pien Tze Huang () Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells.

Xi Chen, Fei Qi, A-Ling Shen, Jian-Feng Chu, Thomas Joseph Sferra, You-Qin Chen, Jun Peng

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xi ChenAcademy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
Fei QiAcademy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
A-Ling ShenAcademy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
Jian-Feng ChuAcademy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
Thomas Joseph SferraSchool of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.
You-Qin ChenAcademy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
Jun PengAcademy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. pjunlab@hotmail.com.
Fujian University of Traditional Chinese Medicine · CNCase Western Reserve University · USFuzhou General Hospital of Nanjing Military Command · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of Pien Tze Huang (, PZH) on breast cancer chemoresistance and related epithelial-mesenchymal transition (EMT) and investigate the underlying mechanisms.

methods3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was used to determine the cell viability. Adriamycin (ADR) staining observed by fluorescence microscope was performed to detect the accumulation of ADR. Transwell assay was used to analyze the cell migration and invasion. Western-blot was performed to detect the protein expression of related genes.

resultsMCF-7/ADR cells were resistant to ADR treatment, and PZH treatment inhibited the viability of MCF-7/ADR cells in a dose-dependent manner. PZH treatment also increased the intercellular accumulation of ADR and down-regulated the expression of ABCG2 and ABCB1 in MCF-7/ADR cells (P<0.05). In addition, PZH treatment inhibited EMT, migration and invasion of MCF-7/ADR cells (P<0.05). Moreover, PZH suppressed activation of transforming growth factor β1 (TGF-β) signaling in MCF-7/ADR cells (P<0.05).

conclusionPZH treatment can effectively overcome chemoresistance via down regulating ABCG2, ABCB1 and inhibit EMT in ADR resistant human breast cancer cells via suppression of the TGF-β1 pathway.

Indexed as

Drug Resistance, NeoplasmEpithelial-Mesenchymal TransitionATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2Breast NeoplasmsCadherinsCell SurvivalDoxorubicinDrugs, Chinese HerbalFemaleHumansMCF-7 CellsNeoplasm MetastasisNeoplasm ProteinsSignal TransductionTransforming Growth Factor beta1ABCB1 protein, humanABCG2 protein, humanATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2CadherinsDoxorubicinDrugs, Chinese HerbalNeoplasm Proteinspien tze huangTGFB1 protein, humanTransforming Growth Factor beta1breast cancerchemoresistanceChinese medicineepithelial-mesenchymal transitionPien Tze Huang

Identifiers

PMID30132246
OpenAlexW2888109810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.